Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure
Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure
复制标题
DOI：
10.1161/01.cir.0000044914.42696.6a
复制
发表时间：
2003-01-21
期刊：
影响因子：
37.8
通讯作者：
Androne, AS
中科院分区：
文献类型：
--
作者：
Mancini, DM;Katz, SD;Androne, AS
背景：慢性心力衰竭（CHF）患者经常贫血。血红蛋白的增加可以通过增加氧气输送来提高运动表现。我们研究了促红细胞生成素（EPO）对伴有心力衰竭的贫血患者运动表现的影响。方法和结果：26例年龄为57+/-11岁的贫血患者随机接受EPO（每周15,000至30,000 IU）或安慰剂治疗3个月。基线和治疗结束时测量的参数包括血液参数（血红蛋白、红细胞压积、血浆容量）、运动参数（峰值耗氧量[(V) / O-2]、运动持续时间、6分钟步行）、肌肉有氧代谢（(V) / O-2和近红外恢复的一半时间）和前臂血管舒张功能。EPO在所有患者中耐受性良好。EPO组12例患者感觉改善，安慰剂组1例(P
Background-Patients with chronic heart failure (CHF) are frequently anemic. An increase in hemoglobin could enhance exercise performance by increasing oxygen delivery. We investigated the effect of erythropoietin (EPO) on exercise performance in anemic patients with CHF.Methods and Results-Twenty-six anemic patients aged 57+/-11 years were randomized to receive EPO (15 000 to 30 000 IU per week) or placebo for 3 months. Parameters measured at baseline and end therapy included blood parameters (hemoglobin, hematocrit, plasma volume), exercise parameters (peak oxygen consumption [(V) over dot O-2], exercise duration, 6-minute walk), muscle aerobic metabolism (half-time of (V) over dot O-2 and near infrared recovery), and forearm vasodilatory function. EPO was well tolerated by all patients. Twelve patients in the EPO group felt improvement versus 1 in the placebo group (P